Search Results

You are looking at 91 - 100 of 178 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Lauren Nye, Timothy K. Huyck, and William J. Gradishar

-CSF) with each cycle and the lack of safety data on G-CSF in pregnancy. Tamoxifen and trastuzumab are contraindicated in pregnancy because of the high frequency of congenital abnormalities and poor fetal outcomes. 15 , 17 – 19 Radiation therapy may be a

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli

an opposed tangent technique, which delivered 50.4 Gy in 28 fractions to the whole breast, followed by a 10-Gy boost to the lumpectomy cavity. She was then lost to follow-up and did not receive the intended course of adjuvant tamoxifen nor the

Full access

Erica L. Mayer, Nancy U. Lin, and Harold J. Burstein

trastuzumab: a clinically active regimen [abstract] . J Clin Oncol 2005 ; 23 ( suppl 1 ): Abstract 559 . 68. Chu I Blackwell K Chen S . The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell

Full access

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen

endocrine therapy with goserelin and tamoxifen. This regimen was continued for 2 years until the patient experienced relapse with multiple lung metastases. She received various therapies over the next 4.5 years, including chemotherapy, endocrine therapy

Full access

Susan Lester

cancer. 10 If the rate of unrelated cancers in the opposite breast is the same as those in the same breast, then approximately half of the ipsilateral recurrences could be biologically new cancers. The greater effectiveness of radiation, tamoxifen, and

Full access

Michelle E. Melisko and Joseph B. Narus

-term use of hormonal agents such as tamoxifen and aromatase inhibitors can cause vasomotor and musculoskeletal symptoms. 3 For both men and women who have had surgery for rectal cancer, sexual problems afterward are “common, multifactorial, inadequately

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

the risk of death compared with standard chemotherapy, 27 and overtreatment with lumpectomy plus tamoxifen and radiation therapy has shown no benefit compared with lumpectomy plus adjuvant therapy with tamoxifen alone. 28 In our study of patients

Full access

Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force

amplification and response to either tamoxifen or aromatase inhibitors. 85 , 88 – 91 Despite inconsistent data, however, HER2 status has been, and may continue to be, considered in clinical decision-making involving hormonal therapies. 92 Trastuzumab with

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

lumpectomy alone, both with tamoxifen for 5 years. Locoregional recurrence rates were 1% in the lumpectomy, radiation, and tamoxifen arm and 4% in the lumpectomy plus tamoxifen arm. No differences were seen in overall survival, disease-free survival, or need

Full access

Robert A. Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Sorin Buga, Charles Cleeland, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Mark Green, Nora A. Janjan, Mihir M. Kamdar, Michael H. Levy, Maureen Lynch, Rachel M. McDowell, Natalie Moryl, Suzanne A. Nesbit, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan G. Urba, Sharon M. Weinstein, Mary Dwyer, and Rashmi Kumar

are known inhibitors of hepatic drug metabolism via inhibition of cytochrome P450 enzymes, especially CYP2D6. Tamoxifen is an estrogen receptor blocker commonly used in patients with hormone receptor-positive breast cancer. Tamoxifen undergoes